Arvinas and Pfizer’s Vepdegestrant Boosts Survival in Breast Cancer
June 2, 2025
Vepdegestrant was generally well tolerated, with few discontinuations and low rates of gastrointestinal-related adverse events Arvinas, Inc. announced detailed results from the Phase 3 VERITAC-2